Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus AZITHROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus AZITHROMYCIN.
AZASITE vs AZITHROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
None Documented
None Documented
Clinical Note
moderateAzithromycin + Norfloxacin
"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateAzithromycin + Ibandronate
"Azithromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateAzithromycin + Indapamide
"Azithromycin may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateAzithromycin + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic